Labiotech.eu

Inside Labiotech 7 Nov 2018

What’s The Impact Of Labiotech On The Biotech Ecosystem? (Hint: It’s High … )

Our mission is to deliver the best content and to bring together people making up the biotech ecosystem in Europe. How do we do it? Is it actually impactful? If so, how? Let me try to answer… To start off, let’s take some perspective, what’s the current state of the connectivity of the biotech industry […]

November 7, 2018 - 3 minutesmins - By Philip Hemme

bone therapeutics bone disease hip header

News and Trends 7 Nov 2018

Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease

Bone Therapeutics is going to discontinue its cell therapy Phase III trial after finding little hope of success for patients with the bone disease osteonecrosis. If all had gone as planned, the full trial would have monitored 118 patients over 24 months. However, an interim analysis on 44 patients after 12 months found little evidence […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

In Depth 7 Nov 2018

Biohacking: Democratization of Science or Just a Quirky Hobby?

The biohacking movement is making scientific research accessible to everyone under the form of low-cost community labs. What does it mean to be a biohacker and how is it changing the way we do science? Scientific research is undoubtedly an arduous endeavor. One that requires highly trained and skilled scientists and that can only be […]

November 7, 2018 - 5 minutesmins - By External Contributor

autoimmune liver disease Genkyotex organ

News and Trends 7 Nov 2018

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

chikungunya virus mosquito Themis bioscience

News and Trends 6 Nov 2018

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead candidate gets positive results in Phase II. Themis Bioscience measured the blood levels of antibodies against the company’s vaccine in 263 healthy volunteers. Four weeks after injections of its lead candidate vaccine, the participants had produced antibodies to protect themselves […]

November 6, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Nov 2018

Potential HIV Treatment Shows Early Stage Promise

According to Phase I/IIa trial results from an Israeli biotech, an HIV drug reduced patients’ HIV levels by up to 99%, and might one day become a new treatment for the infection. The trial, run by Zion Medical, found that the synthetic peptide drug reduced the level of viral RNA in patients’ blood by up to […]

November 6, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Nov 2018

Series C Bags German Company €17M for Irregular Heartbeat Treatment

Omeicos Therapeutics has secured €17M in a Series C round to fund clinical development of its lead treatment for irregular heartbeat. Robert Fischer, CEO of the German biopharmaceutical company, told me that getting the attention of investors such as the Dutch company Forbion, which led the round, was just as helpful as the money itself. […]

November 5, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Nov 2018

DNA Repair Treatment Shows Early Promise for Treating Cancer

Paris-based Onxeo has proved in humans the potential of a cancer treatment that interferes with DNA repair mechanisms. The therapy has potential to work in a wide range of tumors without cancer cells becoming resistant. Onxeo has reported preliminary results from an ongoing Phase I trial in which six different doses will be tested. […]

November 5, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2018

Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition

The Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment, Oxabact, in patients with a rare genetic condition that causes kidney failure. The results came from an interim analysis one year into a three-year trial, where Oxthera is testing its gut microbiome treatment on patients with primary hyperoxaluria type […]

November 2, 2018 - 2 minutesmins - By Jonathan Smith

Startup Scout 2 Nov 2018

This Biotech Uses Metal Alloys to Reshape Your Bones

We venture up to the North European climes of Finland this week. In the city of Espoo, Synoste is developing bone lengthening devices made of smart malleable materials. Mission: To modernize bone lengthening devices with new techniques such as using malleable metals with wireless control. People born with discrepancies in limb length often suffer from […]

November 2, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Nov 2018

Llama Antibodies Could Be the Key to Universal Flu Prevention

Researchers have developed a new approach to prevent the flu that can protect against all seasonal strains of the virus. It also has potential to be effective for those that cannot get vaccinated. In a paper published in Science today, researchers at Janssen and The Scripps Research Institute have revealed a new approach to prevent […]

November 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Orchard therapeutics gene therapy header

News and Trends 1 Nov 2018

Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List

Orchard Therapeutics, a British company developing gene therapy for rare genetic diseases, has launched its Nasdaq IPO and is now reportedly worth $1.25B (€1B). This IPO propels Orchard to the handful of European biotechs worth €1B or more. The new money might help with the marketing and manufacture of Strimvelis, an EMA-approved gene therapy for […]

November 1, 2018 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What’s The Impact Of Labiotech On The Biotech Ecosystem? (Hint: It’s High … )

Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease

Biohacking: Democratization of Science or Just a Quirky Hobby?

Solid Phase II Performance for French Autoimmune Liver Disease Drug

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

Potential HIV Treatment Shows Early Stage Promise

Series C Bags German Company €17M for Irregular Heartbeat Treatment

DNA Repair Treatment Shows Early Promise for Treating Cancer

Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition

This Biotech Uses Metal Alloys to Reshape Your Bones

Llama Antibodies Could Be the Key to Universal Flu Prevention

Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!